Effect of Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone on Platinum-Resistant Recurrent Ovarian Cancer
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Oncology"
DOI: 10.1001/jamaoncol.2022.2253
Abstract: Key Points Question Does the addition of apatinib, a vascular endothelial growth factor receptor 2 tyrosine kinase inhibitor, to treatment with pegylated liposomal doxorubicin (PLD) improve progression-free survival in patients with platinum-resistant recurrent ovarian cancer?… read more here.
Keywords: pegylated liposomal; recurrent ovarian; platinum resistant; liposomal doxorubicin ... See more keywords
Antennapedia-derived positively-charged peptide faces multiple problems upon their usage as targeting ligand for liposomal doxorubicin.
Sign Up to like & getrecommendations! Published in 2021 at "Biotechnology progress"
DOI: 10.1002/btpr.3202
Abstract: The positively-charged peptide antp derived from Antennapedia transcription protein is demonstrated to mediate the liposome translocation across the cell membrane. In the current investigation, we prepared a stable liposomal doxorubicin (Dox) formulation and targeted it… read more here.
Keywords: antp; charged peptide; positively charged; liposomal doxorubicin ... See more keywords
Phase 1 trial of ADI‐PEG 20 and liposomal doxorubicin in patients with metastatic solid tumors
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Medicine"
DOI: 10.1002/cam4.4446
Abstract: Arginine depletion interferes with pyrimidine metabolism and DNA damage repair pathways. Preclinical data demonstrated that depletion of arginine by PEGylated arginine deiminase (ADI‐PEG 20) enhanced liposomal doxorubicin (PLD) cytotoxicity in cancer cells with argininosuccinate synthase… read more here.
Keywords: liposomal doxorubicin; solid tumors; adi peg; metastatic solid ... See more keywords
Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B‐cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi
Sign Up to like & getrecommendations! Published in 2018 at "Hematological Oncology"
DOI: 10.1002/hon.2425
Abstract: The purpose of this phase 2, multicenter study was to determine the activity and safety of nonpegylated liposomal doxorubicin as part of “R‐COMP” combination in patients with diffuse large B‐cell lymphoma and coexisting cardiac disorders.… read more here.
Keywords: patients diffuse; nonpegylated liposomal; large cell; liposomal doxorubicin ... See more keywords
Evaluation of the in vitro and in vivo effect of liposomal doxorubicin along with oncolytic Newcastle disease virus on 4T1 cell line: Animal preclinical research
Sign Up to like & getrecommendations! Published in 2023 at "Veterinary Medicine and Science"
DOI: 10.1002/vms3.1109
Abstract: Abstract Background Breast cancer is one of the most common malignancies in women, with one in 20 globally. Oncolytic viruses have recently been the first step in the biological treatment of cancer, either genetically engineered… read more here.
Keywords: newcastle disease; cell line; liposomal doxorubicin; disease virus ... See more keywords
Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: use of left ventricular ejection fraction is of unproven value
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-017-3420-8
Abstract: PurposeOne of the great conundrums for both oncologists and cardiologists is how to best monitor the potential and actual cardiotoxicity of doxorubicin. Pegylated-liposomal doxorubicin (PLD) has a safer cardiotoxicity profile than bolus administration of doxorubicin.… read more here.
Keywords: doxorubicin induced; pegylated liposomal; pld; patients receiving ... See more keywords
Development of cutaneous squamous cell carcinoma after prolonged exposure to pegylated liposomal doxorubicin and hand–foot syndrome: a newly recognized toxicity
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-019-03849-8
Abstract: Pegylated liposomal doxorubicin (PLD) can be administered for prolonged periods with minimal toxicity. The risk of cutaneous squamous cell carcinoma (SCC) with this therapy has not been reported. We describe cutaneous SCC of the plantar… read more here.
Keywords: pegylated liposomal; cell; squamous cell; cutaneous squamous ... See more keywords
Pegylated liposomal doxorubicin-induced renal toxicity in retroperitoneal liposarcoma: a case report and literature review
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-020-04203-z
Abstract: Doxorubicin is one of the most active drugs for sarcoma. Pegylated liposomal doxorubicin (PLD) is a unique formulation of doxorubicin, which carries a more favorable toxicity profile in comparison with free doxorubicin. The main toxicity… read more here.
Keywords: liposomal doxorubicin; pld; case; toxicity ... See more keywords
A phase II randomized controlled study of pegylated liposomal doxorubicin and carboplatin vs. gemcitabine and carboplatin for platinum-sensitive recurrent ovarian cancer (GOTIC003/intergroup study)
Sign Up to like & getrecommendations! Published in 2019 at "International Journal of Clinical Oncology"
DOI: 10.1007/s10147-019-01471-5
Abstract: PurposeTo compare the efficacy, safety, and tolerability profiles of pegylated liposomal doxorubicin and carboplatin (PLDC) with those of gemcitabine and carboplatin (GC) for the treatment of patients with platinum-sensitive recurrent ovarian cancer.MethodsOvarian cancer patients with… read more here.
Keywords: pegylated liposomal; study; carboplatin; cancer ... See more keywords
Efficacy and Safety of Neoadjuvant Treatment with Bevacizumab, Liposomal Doxorubicin, Cyclophosphamide and Paclitaxel Combination in Locally/Regionally Advanced, HER2-Negative, Grade III at Premenopausal Status Breast Cancer: A Phase II Study
Sign Up to like & getrecommendations! Published in 2018 at "Clinical Drug Investigation"
DOI: 10.1007/s40261-018-0655-z
Abstract: BackgroundIn the era of personalized therapy, targeted treatment in specific patient populations is mandated.ObjectiveWe evaluated the efficacy and safety of neoadjuvant treatment on locally advanced breast cancer (LABC) with a monoclonal agent against vascular endothelial… read more here.
Keywords: doxorubicin cyclophosphamide; breast; neoadjuvant treatment; treatment ... See more keywords
Pegylated liposomal doxorubicin (Caelyx®) interference with the spectrophotometric Jaffe method for quantitative determination of creatinine in human plasma.
Sign Up to like & getrecommendations! Published in 2017 at "Clinical biochemistry"
DOI: 10.1016/j.clinbiochem.2016.12.002
Abstract: • We investigated the in vitro and in vivo pegylated liposomal doxorubicin interference on plasma creatinine determination. read more here.
Keywords: pegylated liposomal; plasma; creatinine; interference ... See more keywords